PPARA and neurodegenerative disease: Numerous PPAR agonists/substances, for instance, pioglitazone, rosiglitazone, GW-501516, L-165041, GW0742, fenofibrate, benzafibrate, and MHY908 have been reported to act at the transcriptional level and thereby emerge as neoteric and propitious targets in the therapy of neurodegenerative diseases.